Last $6.99 USD
Change Today -0.03 / -0.43%
Volume 439.0K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 01:40 PM

Progenics Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 01:40 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 02:25 PM

Progenics Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 02:25 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reports Intangible Impairment Charges for the Third Quarter Ended September 30, 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $41,656,000 against $867,000 a year ago. Operating income was $36,736,000 against operating loss of $10,512,000 a year ago. Net income before income tax benefit was $36,748,000 against net loss before income tax benefit of $10,500,000 a year ago. Net income was $36,975,000 or $0.51 per diluted share against net loss of $10,500,000 or $0.17 per share a year ago. The revenue was up from 2013, reflecting an increase in collaboration revenue of $39.9 million, primarily resulting from the recognition of the $40 million milestone from Salix. For the nine months, the company reported total revenue of $44,948,000 against $4,894,000 a year ago. Operating income was $16,324,000 against operating loss of $34,057,000 a year ago. Net income before income tax benefit was $16,361,000 against net loss before income tax benefit of $34,021,000 a year ago. Net income was $16,589,000 or $0.24 per diluted share against net loss of $34,021,000 or $0.63 per share a year ago. For the third quarter, the company reported intangible impairment charges of $576,000.

Progenics Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 07, 2014

Progenics Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 07, 2014

Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

Progenics Pharmaceuticals, Inc. announced that data from a Phase 2 trial of its PSMA imaging agent candidate, 1404, have been presented at the 27th Annual European Association of Nuclear Medicine (EANM) Congress being held in Gothenburg, Sweden. 1404 is a targeted small molecule designed to 'visualize' prostate cancer by targeting prostate specific membrane antigen. Complete results from the Phase 2 trial in high-risk patients undergoing radical prostatectomy were presented by Gabriella Dabasi, Ph.D. of the Department of Nuclear Medicine at Semmelweis University in Budapest, Hungary, and included previously reported sensitivity and accuracy data for 1404, data related to the uptake of 1404 in the lobes of the prostate gland, and new data on the detection of metastatic prostate cancer in the lymph nodes using SPECT/CT with 1404. In the Phase 2 trial, SPECT/CT imaging with 1404 showed 94% sensitivity in detecting and imaging cancer in the prostate gland of high-risk patients prior to prostatectomy. In addition, 1404 was more sensitive than MRI in detecting primary prostate cancer (94% vs. 86%) and was a good predictor of lymph node involvement at prostatectomy. SPECT/CT imaging with 1404 identified 14 (19%) more patients with suspicious lymph node sites than MRI. Uptake of 1404 in the lobes of the prostate gland showed a highly significant correlation with Gleason score (p<0.0001). The data also showed uptake of 1404 in the primary tumor was significantly lower in treated patients (p<0.0001), corresponding to a decrease in PSA over time observed in these treated patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $6.99 USD -0.03

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.64 USD +0.07
CTI BioPharma Corp $2.36 USD +0.05
Dynavax Technologies Corp $15.35 USD +0.30
Inovio Pharmaceuticals Inc $9.11 USD -0.09
ZIOPHARM Oncology Inc $4.76 USD +0.07
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 57.4x
Price/Sales 10.1x
Price/Book 3.6x
Price/Cash Flow 56.4x
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.